End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
5-day change
1st Jan Change
19,710
KRW
-0.05%
-0.66%
-16.66%
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Ilsung Pharmaceuticals Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 1,308.6 million compared to KRW 1,157.25 million a year ago. Net income was KRW 15,496.38 million compared to KRW 530.58 million a year ago.
Basic earnings per share from continuing operations was KRW 10,580 compared to KRW 355 a year ago. Basic earnings per share was KRW 10,580 compared to KRW 355 a year ago.
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.
23-08-10
CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.
23-08-10
CI
Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback announced on February 13, 2023, has expired with 598,487 shares, representing 29.77% for KRW 14,994.85 million.
23-08-10
CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.
23-05-15
CI
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Ilsung Pharmaceuticals Co., Ltd. announces an Equity Buyback for KRW 15,000 million worth of its shares.
23-02-13
CI
Ilsung Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
23-02-12
CI
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 9, 2022.
22-05-10
CI
Ilsung Pharmaceuticals Co. Ltd.s Equity Buyback announced on February 9, 2022, has expired with 50,935 shares, representing 3.32% for KRW 4,220.26 million.
22-05-08
CI
Ilsung Pharmaceuticals Co., Ltd. announces an Equity Buyback for 53,200 shares.
22-02-09
CI
Ilsung Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
22-02-08
CI
Cheil Industries Inc. completed the acquisition of Samsung C&T Corporation from a group of shareholders.
15-08-30
CI
Ilsung Seeks To Sell Stake In Samsung C&T
15-08-07
CI
Samsung C&T : Proxy advisor urges Samsung C&T holders to reject $8 billion merger
15-07-01
RE
Samsung C&T : Cheil, pitching $8 billion merger, pledges higher returns
15-06-30
RE
Ilsung Pharmaceuticals Co. Ltd.(KOSE:A003120) added to Russell Global Index
15-06-29
CI
Cheil Industries Inc. agreed to acquire Samsung C&T Corporation from a group of shareholders for KRW 8.4 trillion.
15-05-25
CI
Tranche Update on Ilsung Pharmaceuticals Co. Ltd.'s Equity Buyback Plan announced on October 11, 2013.
14-01-13
CI
Ilsung Pharmaceuticals Co. Ltd.s Equity Buyback announced on October 11, 2013 has expired with 661 shares, representing 0.05% for KRW 51.45 million.
14-01-12
CI
Ilsung Pharmaceuticals Co. Ltd. authorizes a Buyback Plan.
13-10-10
CI
Ilsung Pharmaceuticals Co. Ltd. announces an Equity Buyback for 30,000 shares.
13-10-10
CI
Ilsung Pharmaceuticals Co. Ltd.'s Equity Buyback has expired
13-07-15
CI
Ilsung Pharmaceuticals Co. Ltd. announces an Equity Buyback
13-04-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Ilsung IS Co Ltd, formerly Ilsung Pharmaceutical Co Ltd, is a Korea-based company mainly engaged in the pharmaceuticals manufacture and sale business. The Companyâs products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The Company distributes its products through wholesalers, hospitals, pharmacies and others. The Company also provides consignment production services.
More about the company
1st Jan change
Capi.
-16.66% 102M +21.28% 43.92B +24.47% 23.09B +19.22% 15.35B +12.87% 13.61B +44.67% 12.02B -9.92% 7B -0.05% 6.79B -8.87% 5.73B +13.07% 5.6B
Generic Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**